// App-Quantinova.ai

378 : Exploring intermittent dosing schedules for the Pan PI3K/mTor inhibitor PQR309

Researchers

Presenter

  • Karin Jorga

Principal Investigators

  • Debora Schmitz

  • Natasa Cmiljanovic

  • Doriano Fabbro

  • Sasa Dimitrijevic

Medical Centers

  • KarinJorga GmbH, Basel, Switzerland

  • Piqur Therapeutics AG, Basel, Switzerland

Locations

  • Switzerland

Companies

  • Karin Jorga Life Sci

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

Drug/Treatment

  • PQR309

Outcome

  • N/A

Study Design

  • Pharmacokinetics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved